
ASCO: Lack of Benefit Seen for Indefinite-Duration Immunotherapy in NSCLC
Fixed-duration immunotherapy in NSCLC offers similar survival benefits as indefinite treatment. Consider stopping therapy at two years. Read more.












By subscribing, you consent to receive emails from BlackDoctor.pro You may unsubscribe at any time. Privacy Policy & Terms of Service.
Are you a healthcare professional? Register with us today!